查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606341

急性躁動和攻擊性治療市場； - 2024-2034 年全球產業分析、規模、佔有率、成長、趨勢與預測

Acute Agitation and Aggression Treatment Market; - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 213 Pages | 商品交期: 2-10個工作天內

價格

急性激動和攻擊性治療市場 - 報告範圍

TMR 關於全球急性激動和攻擊性治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得2024 年至2034 年預測期內市場指標的寶貴見解。市場的收入2018-2034 年期間躁動和攻擊性治療市場，以 2024 年為基準年，2034 年為預測年。報告也提供了2024年至2034年全球急性激動和攻擊行為治療市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解急性激動和攻擊性治療市場。

市場概況
2023年市場價值 50 億美元
2034 年市場價值 82 億美元
複合年成長率 4.6%

該報告深入研究了全球急性躁動和攻擊行為治療市場的競爭格局。全球急性激動和攻擊性治療市場的主要參與者已經確定，並且每一位參與者都根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球急性激動和攻擊性治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年全球市場分析與預測

第 5 章：關鍵見解

  • 治療方案
  • 市場參與者採取的關鍵策略
  • 各國心理健康支出
  • 醫療保健產業概況
  • PESTEL分析
  • 波特的五力分析
  • 管道分析
  • 監管情境評估
  • 主要國家的報銷情況
  • 急性激動和攻擊性障礙的流行病學
  • 供應鏈分析
  • 重要行業活動

第 6 章：全球市場分析與預測：依治療方法

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依處理方式，2020-2034年
    • 第一代抗精神病藥物：
      • 氯丙嗪
      • 氟哌啶醇
    • 第二代抗精神病藥
      • 喹硫平
      • 奧氮平
      • 齊拉西酮
    • 苯二氮平類
      • 勞拉西泮
      • 咪達唑侖
    • Alpha-2 腎上腺素激動劑
      • 可樂定
      • 右美托咪定
    • 其他
  • 市場吸引力分析：按處理方式

第 7 章：全球市場分析與預測：依指標分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依指標分類，2020-2034
    • 酒精戒斷
    • 躁鬱症
    • 失智
    • 沮喪
    • 藥物引起的躁動和攻擊性
    • 精神分裂症
    • 其他
  • 市場吸引力分析：依指標分類

第 8 章：全球市場分析與預測：按配銷通路

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2020-2034
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 市場吸引力分析：按配銷通路

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020-2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第15章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • Eli Lilly and Company
    • Pfizer, Inc.
    • GlaxoSmithKline
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • Amneal Pharmaceuticals LLC
    • F. Hoffmann-La Roche Ltd
    • Bausch Health Companies, Inc.
    • Apotex, Inc.
Product Code: TMRGL72345

Acute Agitation and Aggression Treatment Market - Scope of Report

TMR's report on the global acute agitation and aggression treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global acute agitation and aggression treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute agitation and aggression treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute agitation and aggression treatment market.

Market Snapshot
Market Value in 2023US$ 5 Bn
Market Value in 2034US$ 8.2 Bn
CAGR4.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute agitation and aggression treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute agitation and aggression treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute agitation and aggression treatment market.

The report delves into the competitive landscape of the global acute agitation and aggression treatment market. Key players operating in the global acute agitation and aggression treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute agitation and aggression treatment market profiled in this report.

Key Questions Answered in Global acute agitation and aggression treatment Market Report:

  • What is the sales/revenue generated by acute agitation and aggression treatment across all regions during the forecast period?
  • What are the opportunities in the global acute agitation and aggression treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Acute Agitation and Aggression Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global acute agitation and aggression treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute agitation and aggression treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute agitation and aggression treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Agitation and Aggression Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Treatment Protocol
  • 5.2. Key Strategies adopted by Market Players
  • 5.3. Mental Health Spendings by Countries
  • 5.4. Healthcare Industry Overview
  • 5.5. PESTEL Analysis
  • 5.6. PORTER's Five Forces Analysis
  • 5.7. Pipeline Analysis
  • 5.8. Regulatory Scenario Assessment
  • 5.9. Reimbursement Scenario by Key Countries
  • 5.10. Epidemiology of Acute Agitations and Aggression Disorders
  • 5.11. Supply Chain Analysis
  • 5.12. Key Industry Events

6. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Treatment Approach

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Approach, 2020-2034
    • 6.3.1. First-Generation Anti-Psychotics:
      • 6.3.1.1. Chlorpromazine
      • 6.3.1.2. Haloperidol
    • 6.3.2. Second-Generation Anti-Psychotics
      • 6.3.2.1. Quetiapine
      • 6.3.2.2. Olanzapine
      • 6.3.2.3. Ziprasidone
    • 6.3.3. Benzodiazepines
      • 6.3.3.1. Lorazepam
      • 6.3.3.2. Midazolam
    • 6.3.4. Alpha-2 Adrenergic Agonist
      • 6.3.4.1. Clonidine
      • 6.3.4.2. Dexmedetomidine
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Treatment Approach

7. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication, 2020-2034
    • 7.3.1. Alcohol Withdrawal
    • 7.3.2. Bipolar Disorder
    • 7.3.3. Dementia
    • 7.3.4. Depression
    • 7.3.5. Drug-induced agitation and aggression
    • 7.3.6. Schizophrenia
    • 7.3.7. Others
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 10.2.1. First-Generation Anti-Psychotics:
      • 10.2.1.1. Chlorpromazine
      • 10.2.1.2. Haloperidol
    • 10.2.2. Second-Generation Anti-Psychotics
      • 10.2.2.1. Quetiapine
      • 10.2.2.2. Olanzapine
      • 10.2.2.3. Ziprasidone
    • 10.2.3. Benzodiazepines
      • 10.2.3.1. Lorazepam
      • 10.2.3.2. Midazolam
    • 10.2.4. Alpha-2 Adrenergic Agonist
      • 10.2.4.1. Clonidine
      • 10.2.4.2. Dexmedetomidine
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Indication, 2020-2034
    • 10.3.1. Alcohol Withdrawal
    • 10.3.2. Bipolar Disorder
    • 10.3.3. Dementia
    • 10.3.4. Depression
    • 10.3.5. Drug-induced agitation and aggression
    • 10.3.6. Schizophrenia
    • 10.3.7. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2020-2034
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Treatment Approach
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 11.2.1. First-Generation Anti-Psychotics:
      • 11.2.1.1. Chlorpromazine
      • 11.2.1.2. Haloperidol
    • 11.2.2. Second-Generation Anti-Psychotics
      • 11.2.2.1. Quetiapine
      • 11.2.2.2. Olanzapine
      • 11.2.2.3. Ziprasidone
    • 11.2.3. Benzodiazepines
      • 11.2.3.1. Lorazepam
      • 11.2.3.2. Midazolam
    • 11.2.4. Alpha-2 Adrenergic Agonist
      • 11.2.4.1. Clonidine
      • 11.2.4.2. Dexmedetomidine
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Indication, 2020-2034
    • 11.3.1. Alcohol Withdrawal
    • 11.3.2. Bipolar Disorder
    • 11.3.3. Dementia
    • 11.3.4. Depression
    • 11.3.5. Drug-induced agitation and aggression
    • 11.3.6. Schizophrenia
    • 11.3.7. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.5.1. Germany
    • 11.5.2. UK
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Treatment Approach
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 12.2.1. First-Generation Anti-Psychotics:
      • 12.2.1.1. Chlorpromazine
      • 12.2.1.2. Haloperidol
    • 12.2.2. Second-Generation Anti-Psychotics
      • 12.2.2.1. Quetiapine
      • 12.2.2.2. Olanzapine
      • 12.2.2.3. Ziprasidone
    • 12.2.3. Benzodiazepines
      • 12.2.3.1. Lorazepam
      • 12.2.3.2. Midazolam
    • 12.2.4. Alpha-2 Adrenergic Agonist
      • 12.2.4.1. Clonidine
      • 12.2.4.2. Dexmedetomidine
      • 12.2.4.3. Guanabenz
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Indication, 2020-2034
    • 12.3.1. Alcohol Withdrawal
    • 12.3.2. Bipolar Disorder
    • 12.3.3. Dementia
    • 12.3.4. Depression
    • 12.3.5. Drug-induced agitation and aggression
    • 12.3.6. Schizophrenia
    • 12.3.7. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & Newzealend
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Treatment Approach
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 13.2.1. First-Generation Anti-Psychotics:
      • 13.2.1.1. Chlorpromazine
      • 13.2.1.2. Haloperidol
    • 13.2.2. Second-Generation Anti-Psychotics
      • 13.2.2.1. Quetiapine
      • 13.2.2.2. Olanzapine
      • 13.2.2.3. Ziprasidone
    • 13.2.3. Benzodiazepines
      • 13.2.3.1. Lorazepam
      • 13.2.3.2. Midazolam
    • 13.2.4. Alpha-2 Adrenergic Agonist
      • 13.2.4.1. Clonidine
      • 13.2.4.2. Dexmedetomidine
      • 13.2.4.3. Guanabenz
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Indication, 2020-2034
    • 13.3.1. Alcohol Withdrawal
    • 13.3.2. Bipolar Disorder
    • 13.3.3. Dementia
    • 13.3.4. Depression
    • 13.3.5. Drug-induced agitation and aggression
    • 13.3.6. Schizophrenia
    • 13.3.7. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Treatment Approach
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 14.2.1. First-Generation Anti-Psychotics:
      • 14.2.1.1. Chlorpromazine
      • 14.2.1.2. Haloperidol
    • 14.2.2. Second-Generation Anti-Psychotics
      • 14.2.2.1. Quetiapine
      • 14.2.2.2. Olanzapine
      • 14.2.2.3. Ziprasidone
    • 14.2.3. Benzodiazepines
      • 14.2.3.1. Lorazepam
      • 14.2.3.2. Midazolam
    • 14.2.4. Alpha-2 Adrenergic Agonist
      • 14.2.4.1. Clonidine
      • 14.2.4.2. Dexmedetomidine
      • 14.2.4.3. Guanabenz
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Indication, 2020-2034
    • 14.3.1. Alcohol Withdrawal
    • 14.3.2. Bipolar Disorder
    • 14.3.3. Dementia
    • 14.3.4. Depression
    • 14.3.5. Drug-induced agitation and aggression
    • 14.3.6. Schizophrenia
    • 14.3.7. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Treatment Approach
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Eli Lilly and Company
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Pfizer, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. GlaxoSmithKline
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Johnson & Johnson
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Amneal Pharmaceuticals LLC
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. F. Hoffmann-La Roche Ltd
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Bausch Health Companies, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Apotex, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments

Acute Agitation and Aggression Treatment Market

Acute Agitation and Aggression Treatment Industry

Acute Agitation and Aggression Treatment Market Size

Acute Agitation and Aggression Treatment Market Share

Acute Agitation and Aggression Treatment Market Growth

Acute Agitation and Aggression Treatment Market Analysis

Acute Agitation and Aggression Treatment Market Demand

Acute Agitation and Aggression Treatment Market Forecast

Acute Agitation and Aggression Treatment Market Trends

List of Tables

  • Table 01: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 02: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 03: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 04: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 05: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 06: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 07: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 08: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Region, 2020-2034
  • Table 09: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 10: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 11: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 12: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 13: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 14: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 15: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 16: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 19: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 20: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 21: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 22: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 23: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 24: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 25: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 26: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 27: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 28: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 29: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 30: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 31: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 32: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 33: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 34: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 35: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 36: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 37: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 38: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 39: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 40: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 41: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 42: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 43: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 44: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 45: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 46: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 47: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 48: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 02: Global Acute Agitation and Aggression Treatment Market Value Share, by Treatment Approach, 2023
  • Figure 03: Global Acute Agitation and Aggression Treatment Market Value Share, by Indication, 2023
  • Figure 04: Global Acute Agitation and Aggression Treatment Market Value Share, by Distribution Channel, 2023
  • Figure 05: Global Acute Agitation and Aggression Treatment Market Value Share, by Region, 2023
  • Figure 06: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 07: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Treatment Approach, 2023
  • Figure 08: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Treatment Approach, 2034
  • Figure 09: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 10: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by First-Generation Anti-Psychotics, 2020-2034
  • Figure 11: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by First-Generation Anti-Psychotics, 2024 and 2034
  • Figure 12: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Second-Generation Anti-Psychotics, 2020-2034
  • Figure 13: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Second-Generation Anti-Psychotics, 2024 and 2034
  • Figure 14: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Benzodiazepines, 2020-2034
  • Figure 15: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Benzodiazepines, 2024 and 2034
  • Figure 16: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Alpha-2 Adrenergic Agonist, 2020-2034
  • Figure 17: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Alpha-2 Adrenergic Agonist, 2024 and 2034
  • Figure 18: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Others, 2020-2034
  • Figure 19: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Others, 2024 and 2034
  • Figure 20: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 21: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Indication, 2023
  • Figure 22: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Indication, 2034
  • Figure 23: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 24: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Alcohol Withdrawal, 2020-2034
  • Figure 25: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Alcohol Withdrawal, 2024 and 2034
  • Figure 26: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Bipolar Disorder, 2020-2034
  • Figure 27: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Bipolar Disorder, 2024 and 2034
  • Figure 28: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Dementia, 2020-2034
  • Figure 29: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Dementia, 2024 and 2034
  • Figure 30: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Depression, 2020-2034
  • Figure 31: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Depression, 2024 and 2034
  • Figure 32: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Drug-induced agitation and aggression, 2020-2034
  • Figure 33: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Drug-induced agitation and aggression, 2024 and 2034
  • Figure 34: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Schizophrenia, 2020-2034
  • Figure 35: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Schizophrenia, 2024 and 2034
  • Figure 36: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Others, 2020-2034
  • Figure 37: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Others, 2024 and 2034
  • Figure 38: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 39: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Distribution Channel, 2023
  • Figure 40: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Distribution Channel, 2034
  • Figure 41: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 42: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Hospital Pharmacies, 2020-2034
  • Figure 43: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Hospital Pharmacies, 2024 and 2034
  • Figure 44: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Retail Pharmacies, 2020-2034
  • Figure 45: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Retail Pharmacies, 2024 and 2034
  • Figure 46: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Online Pharmacies, 2020-2034
  • Figure 47: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Online Pharmacies, 2024 and 2034
  • Figure 48: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 49: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Region, 2023
  • Figure 50: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Region, 2034
  • Figure 51: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 53: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 54: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 55: North America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 56: North America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 57: North America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 58: North America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 59: North America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: North America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 61: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 62: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 63: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 64: Europe Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 65: Europe Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 66: Europe Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 67: Europe Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 68: Europe Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 69: Europe Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 70: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 71: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 72: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 73: Asia Pacific Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 74: Asia Pacific Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 75: Asia Pacific Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 76: Asia Pacific Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 77: Asia Pacific Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 78: Asia Pacific Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 79: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 80: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 81: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 82: North America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 83: North America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 84: Latin America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 85: Latin America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 86: Latin America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 87: Latin America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 88: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 89: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 90: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 91: Middle East and Africa Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 92: Middle East and Africa Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 93: Middle East and Africa Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 94: Middle East and Africa Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 95: Middle East and Africa Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 96: Middle East and Africa Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034